Astellas invests $256m in cell therapy manufacturing buildout
The company will construct two facilities in Japan and relocate its regenerative medicine facility in the US.
Archives for November 7, 2018
DIA BIOSIMILARS CONFERENCE
The changing biosimilar landscape: Lesser-known firms, blockbuster molecules
As an increasing number of biosimilar developers target the European market, lesser-known firms may explore alternative commercialisation strategies, says Iqvia executive.
Sandoz bows out of US Rituxan biosimilar race
After the business was asked by the US FDA to provide more data to secure an approval for its biosimilar, Sandoz decided not to pursue its regulatory filing any further.